Royalty Pharma (STU:RPD) Retained Earnings : €2,491 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Royalty Pharma Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Royalty Pharma's retained earnings for the quarter that ended in Sep. 2024 was €2,491 Mil.

Royalty Pharma's quarterly retained earnings declined from Mar. 2024 (€2,233 Mil) to Jun. 2024 (€2,209 Mil) but then increased from Jun. 2024 (€2,209 Mil) to Sep. 2024 (€2,491 Mil).

Royalty Pharma's annual retained earnings declined from Dec. 2021 (€1,996 Mil) to Dec. 2022 (€1,855 Mil) but then increased from Dec. 2022 (€1,855 Mil) to Dec. 2023 (€2,309 Mil).

Royalty Pharma Retained Earnings Historical Data

The historical data trend for Royalty Pharma's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Royalty Pharma Retained Earnings Chart

Royalty Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

2,542.69

1,578.76

1,995.83

1,854.67

2,308.62

Royalty Pharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Retained Earnings	Get a 7-Day Free Trial															2,000.20	2,308.62	2,233.25	2,209.40	2,490.98

Royalty Pharma Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Royalty Pharma (STU:RPD) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Royalty Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (STU:RPD) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

RPRX:USA RPRX:Mexico RPD:Germany

Address

110 East 59th Street, New York, NY, USA, 10022

Website

https://www.royaltypharma.com

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.